Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00932672 | Atkins Diet and Prostate Cancer Clinical Trial | terminated | Phase 2 | 45 | Duke UniversityOTHER | 1 | Dec 7, 2015 | clinicaltrials |
| NCT00020735 | Toremifene Followed by Radical Prostatectomy in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 45 | Joel Nelson, MDOTHER | 1 | Dec 2, 2015 | clinicaltrials |
| NCT00110188 |
| Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) |
| completed |
| Phase 2 |
| 39 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 1 |
| Nov 20, 2015 |
| clinicaltrials |
| NCT00741039 | Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older | completed | Phase 2 | 126 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00928174 | Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer | completed | Phase 1 / Phase 2 | 27 | Queen's Medical CenterOTHER | 1 | Nov 11, 2015 | clinicaltrials |
| NCT01898065 | Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer(HYPOXProstat) | completed | Phase 2 | 20 | Institut Cancerologie de l'OuestOTHER | 1 | Nov 9, 2015 | clinicaltrials |
| NCT01795703 | A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel | completed | Phase 2 | 47 | Janssen Research & Development, LLCINDUSTRY | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00524680 | Vitamin D in Treating Patients With Prostate Cancer | completed | Phase 2 | 148 | Roswell Park Cancer InstituteOTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT01541007 | A Study Looking at Novel Scheduling of Cabazitaxel for Patients With Metastatic Prostate Cancer(ConCab) | completed | Phase 2 | 100 | Jeffrey Yachnin M.D., PhD.OTHER | 1 | Nov 2, 2015 | clinicaltrials |
| NCT00853697 | Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer | completed | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 30, 2015 | clinicaltrials |
| NCT00560482 | Efficacy Study of ABR-215050 to Treat Prostate Cancer | completed | Phase 2 | 206 | Active Biotech ABINDUSTRY | 3 | Oct 26, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01530984 | Ipilimumab and GMCSF Immunotherapy for Prostate Cancer | withdrawn | Phase 2 | 0 | Lawrence FongOTHER | 1 | Oct 5, 2015 | clinicaltrials |
| NCT00585416 | Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 23 | University of Wisconsin, MadisonOTHER | 1 | Oct 2, 2015 | clinicaltrials |
| NCT02480010 | A Study of Pertuzumab in Participants With Prostate Cancer | terminated | Phase 2 | 68 | Hoffmann-La RocheINDUSTRY | 6 | Sep 18, 2015 | clinicaltrials |
| NCT00818480 | An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155 | completed | Phase 2 | 10 | Astellas Pharma IncINDUSTRY | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT00777959 | Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) | completed | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2015 | clinicaltrials |
| NCT01897207 | Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Cantonal Hospital of St. GallenOTHER | 0 | Aug 17, 2015 | clinicaltrials |
| NCT00514267 | An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | completed | Phase 1 / Phase 2 | 32 | Astellas Pharma IncINDUSTRY | 1 | Aug 13, 2015 | clinicaltrials |
| NCT01561482 | Study of Metformin With Simvastatin for Men With Prostate Carcinoma | withdrawn | Phase 2 | 0 | Nicholas MitsiadesOTHER | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00936975 | Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jul 16, 2015 | clinicaltrials |
| NCT01436214 | Dose-Escalation and Safety Study of APC-100 for the Treatment of Prostate Cancer | unknown | Phase 1 / Phase 2 | 60 | Adamis Pharmaceuticals CorporationINDUSTRY | 1 | Jul 16, 2015 | clinicaltrials |
| NCT00108732 | A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT02049190 | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 75 | Arno TherapeuticsINDUSTRY | 1 | Jun 24, 2015 | clinicaltrials |
| NCT00058539 | Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer | completed | Phase 2 | 42 | Genentech, Inc.INDUSTRY | 0 | Jun 23, 2015 | clinicaltrials |
| NCT01705652 | Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients(Nexrutine) | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 11, 2015 | clinicaltrials |
| NCT02424513 | A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer | withdrawn | Phase 2 | 0 | ImaginAb, Inc.INDUSTRY | 1 | Jun 2, 2015 | clinicaltrials |
| NCT00118066 | Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia | terminated | Phase 2 | 12 | Rutgers, The State University of New JerseyOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT00743379 | Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 71 | Threshold PharmaceuticalsINDUSTRY | 1 | May 7, 2015 | clinicaltrials |
| NCT00715104 | Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer(NeoACT) | completed | Phase 2 | 42 | DendreonINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00020254 | Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00500110 | Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer | completed | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 28, 2015 | clinicaltrials |
| NCT00975429 | Study Using WST11 in Patients With Localized Prostate Cancer | completed | Phase 2 | 86 | Steba Biotech S.A.OTHER | 3 | Apr 28, 2015 | clinicaltrials |
| NCT02425163 | Shear Wave Elastography of Prostate Cancer(ElaProC) | completed | Phase 2 | 73 | University of MagdeburgOTHER | 1 | Apr 23, 2015 | clinicaltrials |
| NCT00673127 | Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer(KHAD) | completed | Phase 2 | 57 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 22, 2015 | clinicaltrials |
| NCT00176293 | Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer | terminated | Phase 2 | 2 | University of KentuckyOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT02420587 | AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2015 | clinicaltrials |
| NCT00217464 | Fulvestrant in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 17 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00215683 | An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer | completed | Phase 2 / Phase 3 | 137 | Ferring PharmaceuticalsINDUSTRY | 7 | Apr 1, 2015 | clinicaltrials |
| NCT01267266 | Saracatinib in Treating Patients With Prostate Cancer | terminated | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00260611 | Study of Oxaliplatin and Taxotere in Prostate Cancer | completed | Phase 2 | 34 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT01533246 | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2015 | clinicaltrials |
| NCT00080899 | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00694291 | Sorafenib in Hormone Naïve Biochemical Recurrence of Prostate Cancer | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01565512 | Dorsal Penile Block for Post-Robotic Prostatectomy Foley Discomfort | withdrawn | Phase 1 / Phase 2 | 0 | Columbia UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT02159690 | A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | withdrawn | Phase 2 | 0 | Kenneth Pienta, MDOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00151086 | Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 33 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Dec 7, 2015source: clinicaltrials